Liver fibrogenesis in non-alcoholic steatohepatitis

Frontiers in Physiology

Volumn 3 JUL, Issue , 2012, Pages

  Bian, Zhaolian ^a,b   Ma, Xiong ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Non alcoholic fatty liver disease, hepatic stellate cell, hepatic fibrosis, cirrhosis

Indexed keywords

EID: 84866468360     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00248     Document Type: Review

References (95)

1. Adler, M., Taylor, S., Okebugwu, K., Yee, H., Fielding, C., Fielding, G., and Poles, M. (2011). Intrahepatic natural killer T cell populations are increased in human hepatic steatosis. World J. Gastroenterol. 17, 1725-1731
2. Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., and Webber, J. (2008). Randomized, placebo-controlled trial of pioglita-zone in nondiabetic subjects with nonalcoholic steatohepatitis. Gas-troenterology 135, 1176-1184.
3. Asano, T., Watanabe, K., Kubota, N., Gunji, T., Omata, M., Kadowaki, T., and Ohnishi, S. (2009). Adiponectin knockout mice on high fat diet develop fibrosing steatohepati-tis. J. Gastroenterol. Hepatol. 24, 1669-1676.
4. Bataller, R., Sancho-Bru, P., Gines, P., and Brenner, D. A. (2005). Liver fibrogenesis:anew role for the renin-angiotensin system. Antioxid. Redox Signal. 7, 1346-1355.
5. Beaven, S. W., Wroblewski, K., Wang, J., Hong, C., Bensinger, S., Tsukamoto, H., and Tontonoz, P. (2011). Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology 140, 1052-1062.
6. Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., Berria, R., Ma, J. Z., Dwivedi, S., Havranek, R., Fincke, C., DeFronzo, R., Bannayan, G. A., Schenker, S., and Cusi, K. (2006). A placebo-controlled trial of pioglita-zone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297-2307.
7. Bloom, S. R., Kuhajda, F. P., Laher, I., Pi-Sunyer, X., Ronnett, G. V., Tan, T. M., and Weigle, D. S. (2008). The obesity epidemic: pharmacological challenges. Mol. Interv. 8, 82-98.
8. Brun, P., Castagliuolo, I., Pinzani, M., Palu, G., and Martines, D. (2005). Exposure to bacterial cell wall products triggers an inflammatory phe-notype in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G571-G578.
9. Brunt, E. M. (2004). Nonalcoholic steatohepatitis. Semin. Liver Dis. 24, 3-20.
10. Bugianesi, E., Manzini, P., D'Antico, S., Vanni, E., Longo, F., Leone, N., Mas-sarenti, P., and Rizzetto, M. (2004). Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39, 179-187.
11. Cao, Q., Mak, K. M., and Lieber, C. S. (2007). Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells. J. Hepatol. 46, 124-133.
12. Chalasani, N., Deeg, M. A., and Crabb, D. W. (2004). Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99, 1497-1502.
13. Chitturi, S., Abeygunasekera, S., Far-rell, G. C., Holmes-Walker, J., Hui, J. M., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Welt-man, M., and George, J. (2002). NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35, 373-379.
14. Choi, S. S., Syn, W. K., Karaca, G. F., Omenetti, A., Moylan, C. A., Witek, R. P., Agboola,K. M., Jung, Y., Mich-elotti, G. A., and Diehl,A. M. (2010). Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J. Biol. Chem. 285, 36551-36560.
15. Cohen, J. C., Horton, J. D., and Hobbs, H. H. (2011). Human fatty liver disease: old questions and new insights. Science 332, 1519-1523.
16. Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto, G., Furth, E. E., Poli, V., and Taub, R. (1996). Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274, 1379-1383.
17. Day, C. P., and James, O. F. (1998). Steatohepatitis: a tale of two "hits?" Gastroenterology 114, 842-845.
18. De Minicis, S., Bataller, R., and Brenner, D. A. (2006). NADPH oxi-dase in the liver: defensive, offensive, or fibrogenic? Gastroenterology 131, 272-275.
19. De Minicis, S.,Seki, E., Paik,Y. H., Oster-reicher, C. H., Kodama, Y., Kluwe, J., Torozzi, L., Miyai, K., Benedetti, A., Schwabe, R. F., and Brenner, D. A. (2010). Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibro-sis. Hepatology 52, 1420-1430.
20. De Minicis, S., and Svegliati-Baroni, G. (2011). Fibrogenesis in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 5, 179-187.
21. de Oliveira, C. P., Stefano, J. T., de Siqueira, E. R., Silva, L. S., de Campos Mazo,D. F., Lima,V. M., Furuya, C. K., Mello, E. S., Souza, F. G., Rabello, F., Santos, T. E., Nogueira, M. A., Caldwell, S. H., Alves, V. A., and Carrilho, F. J. (2008). Combination of N-acetylcysteine and met-formin improves histological steato-sis and fibrosis in patients with non-alcoholic steatohepatitis. Hepa-tol. Res. 38, 159-165.
22. Deng, Q. G., She, H., Cheng, J. H., French, S. W., Koop, D. R., Xiong, S., and Tsukamoto, H. (2005). Steato-hepatitis induced by intragastric overfeeding in mice. Hepatology 42, 905-914.
23. Deng, Z. B., Liu, Y., Liu, C., Xiang, X., Wang, J., Cheng, Z., Shah, S. V., Zhang, S., Zhang, L., Zhuang, X., Michalek, S., Grizzle, W. E., and Zhang, H. G. (2009). Immature myeloid cells induced by a high-fat diet contribute to liver inflammation. Hepatology 50, 1412-1420.
24. El-Assal, O., Hong, F., Kim, W. H., Radaeva, S., and Gao, B. (2004). IL-6-deficient mice are susceptible to ethanol-induced hepatic steato-sis: IL-6 protects against ethanol-induced oxidative stress and mito-chondrial permeability transition in the liver. Cell. Mol. Immunol. 1, 205-211.
25. Elinav, E., Pappo, O., Sklair-Levy, M., Margalit, M., Shibolet, O., Gomori, M., Alper, R., Thalenfeld, B., Engel-hardt, D., Rabbani, E., and Ilan, Y. (2006). Amelioration of nonalcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels. J. Pathol. 208, 74-81.
26. Farrell, G. C., and Larter, C. Z. (2006). Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatol-ogy 43, S99-S112.
27. Fiorucci, S., Antonelli, E., Rizzo, G., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pellicciari, R., and Morelli, A. (2004). The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroen-terology 127, 1497-1512.
28. Fracanzani, A. L., Valenti, L., Bugianesi, E., Andreoletti, M., Colli, A., Vanni, E., Bertelli, C., Marchesini, G., and Fargion, S. (2008). Risk of severe liver disease in nonalcoholic fatty liver disease with normal amino-transferase levels: a role for insulin resistance and diabetes. Hepatology 48, 792-798.
29. Gastaldelli, A., Harrison, S., Belfort-Aguiar, R., Hardies, J., Balas, B., Schenker, S., and Cusi, K. (2010). Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment. Pharmacol. Ther. 32, 769-775.
30. George, J., Pera, N., Phung, N., Leclercq, I.,Yun Hou, J., and Farrell,G. (2003). Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J. Hepatol. 39, 756-764.
31. Guimaraes, E. L., Franceschi, M. F., Grivicich, I., Dal-Pizzol, F., Moreira, J. C., Guaragna, R. M., Borojevic, R., Margis, R., and Guma, F. C. (2006). Relationship between oxida-tive stress levels and activation state on a hepatic stellate cell line. Liver Int. 26, 477-485.
32. Halaas, J. L., Gajiwala, K. S., Maf-fei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Bur-ley, S. K., and Friedman, J. M. (1995). Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269, 543-546.
33. Hegde, S., Fox, L., Wang, X., and Gumperz, J. E. (2010). Autoreac-tive natural killer T cells: promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells. Immunology 130, 471-483.
34. Ikeda, R., Ishii, K., Hoshikawa, Y., Azumi, J., Arakaki, Y., Yasui, T., Mat-suura, S., Matsumi, Y., Kono, Y., Mizuta, Y., Kurimasa, A., Hisatome, I., Friedman, S. L., Kawasaki, H., and Shiota, G. (2011). Reactive oxygen species and NADPH oxidase 4 induced by transforming growth factor beta1 are the therapeutic targets of polyenylphosphatidylcholine in the suppression of human hepatic stellate cell activation. Inflamm. Res. 60, 597-604.
35. Ishikawa, S., Ikejima, K., Yamagata, H., Aoyama,T., Kon,K.,Arai,K., Takeda, K., and Watanabe, S. (2011). CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. J. Hepatol. 54, 1195-1204.
36. Jin, X., Zimmers, T. A., Perez, E. A., Pierce, R. H., Zhang, Z., and Koniaris, L. G. (2006). Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology 43, 474-484.
37. Jou, J., Choi, S. S., and Diehl, A. M. (2008). Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin. Liver Dis. 28, 370-379.
38. Kaji, K., Yoshiji, H., Kitade, M., Ikenaka, Y., Noguchi, R., Shirai, Y., Aihara, Y., Namisaki, T., Yoshii, J., Yanase, K., Tsujimoto, T., Kawaratani, H., and Fukui, H. (2011). Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G1094-G1104.
39. Kamada, Y., Matsumoto, H., Tamura, S., Fukushima, J., Kiso, S., Fukui, K., Igura, T., Maeda, N., Kihara, S., Funahashi, T., Matsuzawa, Y., Shi-momura, I., and Hayashi, N. (2007). Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J. Hepatol. 47, 556-564.
40. Kamada, Y., Tamura, S., Kiso, S., Mat-sumoto, H., Saji, Y., Yoshida, Y., Fukui, K., Maeda, N., Nishizawa, H., Nagaretani, H., Okamoto, Y., Kihara, S., Miyagawa, J., Shi-nomura, Y., Funahashi, T., and Matsuzawa, Y. (2003). Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125, 1796-1807.
41. Kim, H. J., Higashimori, T., Park, S. Y., Choi, H., Dong, J., Kim, Y. J., Noh, H. L., Cho, Y. R., Cline, G., Kim, Y. B., and Kim, J. K. (2004). Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53, 1060-1067.
42. Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cum-mings, O. W., Ferrell,L. D., Liu,Y. C., Torbenson, M. S., Unalp-Arida, A., Yeh,M.,McCullough,A.J., Sanyal,A. J., and Nonalcoholic Steatohepatitis Clinical Research Network. (2005). Design and validation of a histo-logical scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321.
43. Kodama, Y., Kisseleva, T., Iwaisako, K., Miura, K., Taura, K., De Mini-cis, S., Osterreicher, C. H., Schn-abl, B., Seki, E., and Brenner, D. A. (2009). c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steato-sis to steatohepatitis and fibro-sis in mice. Gastroenterology 137, 1467-1477 e1465.
44. Koek, G. H., Liedorp, P. R., and Bast, A. (2011). The role of oxidative stress in non-alcoholic steatohepatitis. Clin. Chim. Acta 412, 1297-1305.
45. Krawczyk, M., Bonfrate, L., and Port-incasa, P. (2010). Nonalcoholic fatty liver disease. Best Pract. Res. Clin. Gastroenterol. 24, 695-708.
46. Kremer, M., Thomas, E., Milton, R. J., Perry, A. W., van Rooijen, N., Wheeler, M. D., Zacks, S., Fried, M., Rippe, R. A., and Hines, I. N. (2010). Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology 51, 130-141.
47. Kukla, M., Ciupinska-Kajor, M., Kajor, M., Wylezol, M., Zwirska-Korczala, K., Hartleb, M., Berdowska, A., and Mazur, W. (2010a). Liver vis-fatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol. J. Pathol. 61, 147-153.
48. Kukla, M., Zwirska-Korczala, K., Hartleb, M., Waluga, M., Chwist, A., Kajor, M., Ciupinska-Kajor, M., Berdowska, A., Wozniak-Grygiel, E., and Buldak, R. (2010b). Serum chemerin and vaspin in nonalcoholic fatty liver disease. Scand. J. Gastroenterol. 45, 235-242.
49. Kukla, M., Mazur, W., Buldak, R. J., and Zwirska-Korczala, K. (2011). Potential role of leptin, adiponectin and the novel adipokines-visfatin, chemerin and vaspin-in chronic hepatitis. Mol. Med. 17, 1397-1410.
50. Law,K.,and Brunt,E.M.(2010). Nonalcoholic fatty liver disease. Clin. Liver Dis. 14, 591-604.
51. Leclercq, I. A., Lebrun, V. A., Starkel, P., and Horsmans, Y. J. (2007). Intrahepatic insulin resistance in a murine model of steatohepati-tis: effect of PPARgamma agonist pioglitazone. Lab. Invest. 87, 56-65.
52. Lemoine, M., Ratziu, V., Kim, M., Maachi, M., Wendum, D., Paye, F., Bastard, J. P., Poupon, R., Hous-set, C., Capeau, J., and Serfaty, L. (2009). Serum adipokine levels predictive of liver injury in nonalcoholic fatty liver disease. Liver Int. 29, 1431-1438.
53. Li, J., Fan, R., Zhao, S., Liu, L., Guo, S., Wu, N., Zhang, W., and Chen, P. (2011). Reactive oxygen species released from hypoxic hepa-tocytes regulates MMP-2 expression in hepatic stellate cells. Int. J. Mol. Sci. 12, 2434-2447.
54. Li, J., Kuruba, R., Wilson, A., Gao, X., Zhang, Y., and Li, S. (2010). Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand. PLoS ONE 5, e13955. doi:10.1371/journal.pone.0013955
55. Li, Z., Soloski, M. J., and Diehl, A. M. (2005). Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 42, 880-885.
56. Mallat, A., and Lotersztajn, S. (2011). The liver X receptor in hepatic stellate cells: a novel antifibrogenic target? J. Hepatol. 55, 1452-1454.
57. Marra, F., Aleffi, S., Bertolani, C., Petrai, I., and Vizzutti, F. (2005). Review article: the pathogenesis of fibrosis in non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 22(Suppl. 2), 44-47.
58. Marra, F., and Bertolani, C. (2009). Adipokines in liver diseases. Hepa-tology 50, 957-969.
59. Marra, F., Navari, N., Vivoli, E., Galas-tri, S., and Provenzano, A. (2011). Modulation of liver fibrosis by adipokines. Dig. Dis. 29, 371-376.
60. Matsunami, T., Sato, Y., Ariga, S., Sato, T., Kashimura, H., Hasegawa, Y., and Yukawa, M. (2010). Regulation of oxidative stress and inflammation by hepatic adiponectin receptor 2 in an animal model of nonalcoholic steatohepatitis. Int. J. Clin. Exp. Pathol. 3, 472-481.
61. McCarty, M. F. (2011). Full-spectrum antioxidant therapy featuring astax-anthin coupled with lipoprivic strategies and salsalate for management of non-alcoholic fatty liver disease. Med. Hypotheses 77, 550-556.
62. Medici, V., Ali, M. R., Seo, S., Aoki, C. A., Rossaro, L., Kim, K., Fuller, W. D., Vidovszky, T. J., Smith, W., Jiang, J. X., Maganti, K., Havel, P. J., Kamboj, A., Ramsamooj, R., and Török, N. J. (2010). Increased soluble leptin receptor levels in morbidly obese patients with insulin resistance and nonalcoholic fatty liver disease. Obesity (Silver Spring) 18, 2268-2273.
63. Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., Olefsky, J. M., Brenner, D. A., and Seki, E. (2010). Toll-like receptor 9 promotes steatohepati-tis by induction of interleukin-1beta in mice. Gastroenterology 139, 323-334 e327.
64. Nakagami, H., Shimamura, M., Miyake, T., Shimosato, T., Minobe, N., Mori-tani, T., Kiomy Osako, M., Nak-agami, F., Koriyama, H., Kyutoku, M., Shimizu, H., Katsuya, T., and Morishita,R.(2012). Nifedipine prevents hepatic fibrosis in a nonalcoholic steatohepatitis. Mol. Med. Report 5, 37-40.
65. Nakayama, H., Otabe, S., Ueno, T., Hirota, N., Yuan, X., Fukutani, T., Hashinaga, T., Wada, N., and Yamada, K. (2007). Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similartononalcoholic steatohepati-tis. Metab. Clin. Exp. 56, 470-475.
66. Ota, T., Takamura, T., Kurita, S., Mat-suzawa, N., Kita, Y., Uno, M., Aka-hori, H., Misu, H., Sakurai, M., Zen, Y., Nakanuma, Y., and Kaneko, S. (2007). Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterol-ogy 132, 282-293.
67. Paradis, V., Perlemuter, G., Bonvoust, F., Dargere, D., Parfait, B., Vidaud, M., Conti, M., Huet, S., Ba, N., Buffet, C., and Bedossa, P. (2001). High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibro-sis in nonalcoholic steatohepatitis. Hepatology 34, 738-744.
68. Pinzani, M. (2011). Pathophysiology of non-alcoholic steatohepatitis and basis for treatment. Dig. Dis. 29, 243-248.
69. Polyzos, S. A., Kountouras, J., Zavos, C., and Tsiaousi, E. (2010). The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes. Metab. 12, 365-383.
70. Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., Liang, T. J., Yanovski, J. A., Kleiner, D. E., and Hoofna-gle, J. H. (2004). A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39, 188-196.
71. Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., Lenaour, G., Hartmann-Heurtier, A., Bruck-ert, E., Poynard, T., and LIDO Study Group. (2010). Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosigli-tazone therapy (FLIRT 2) extension trial. Hepatology 51, 445-453.
72. Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann-Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J. M., Bernhardt, C., Bruckert, E., Grimaldi, A., Poynard, T., and LIDO Study Group. (2008). Rosiglita-zone for nonalcoholic steatohep-atitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglita-zone therapy (FLIRT) trial. Gas-troenterology 135, 100-110.
73. Renga, B., Mencarelli, A., Migliorati, M., Cipriani, S., D'Amore, C., Distrutti, E., and Fiorucci, S. (2011). SHP-dependent andctivated receptor-gamma by the bile acid sensor farnesoid X receptor counter-ry henotype of liver myofibroblasts. Inflamm. Res. 60, 577-587.
74. Rinella, M. E., and Green, R. M. (2004). The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J. Hepatol. 40, 47-51.
75. Rombouts, K., and Marra, F. (2010). Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohep-atitis. Dig. Dis. 28, 229-235.
76. Sahai, A., Malladi, P., Melin-Aldana, H., Green, R. M., and Whitington, P. F. (2004). Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohep-atitis in a dietary murine model. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G264-G273.
77. Salman, T. A., Allam, N., Azab, G. I., Shaarawy, A. A., Hassouna, M. M., and El-Haddad, O. M. (2010). Study of adiponectin in chronic liver disease and cholestasis. Hepatol. Int. 4, 767-774.
78. Sanyal,A. J., Mofrad, P. S., Contos, M. J., Sargeant, C., Luketic, V. A., Sterling, R. K., Stravitz, R. T., Shiffman, M. L., Clore, J., and Mills, A. S. (2004). A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepati-tis. Clin. Gastroenterol. Hepatol. 2, 1107-1115.
79. Schattenberg, J. M., and Galle, P. R. (2010). Animal models of nonalcoholic steatohepatitis: of mice and man. Dig. Dis. 28, 247-254.
80. Seki, E., De Minicis, S., Osterreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., and Schwabe, R. F. (2007). TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 13, 1324-1332.
81. Sell, H., Divoux, A., Poitou, C., Bas-devant, A., Bouillot, J. L., Bedossa, P., Tordjman, J., Eckel, J., and Clé-ment, K. (2010). Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 95, 2892-2896.
82. Syn, W. K., Oo, Y. H., Pereira, T. A., Karaca, G. F., Jung, Y., Omenetti, A., Witek, R. P., Choi, S. S., Guy, C. D., Fearing, C. M., Teaberry, V., Pereira, F. E., Adams, D. H., and Diehl, A. M. (2010). Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 51, 1998-2007.
83. Tajiri, K., Shimizu, Y., Tsuneyama, K., and Sugiyama, T. (2009). Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogen-esis of nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 21, 673-680.
84. Tarrats, N., Moles, A., Morales, A., Garcia-Ruiz, C., Fernandez-Checa, J. C., and Mari, M. (2011). Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis. Hepatology 54, 319-327.
85. Tilg, H., and Moschen, A. R. (2010). Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepa-tology 52, 1836-1846.
86. Tsukada, S., Parsons, C. J., and Rippe, R. A. (2006). Mechanisms of liver fibrosis. Clin. Chim. Acta 364, 33-60.
87. Urtasun, R., Conde de la Rosa, L., and Nieto, N. (2008). Oxidative and nitrosative stress and fibro-genic response. Clin. Liver Dis. 12, 769-790.
88. Uygun, A., Kadayifci, A., Yesilova, Z., Erdil, A., Yaman, H., Saka, M., Deveci, M. S., Bagci, S., Gulsen, M., Karaeren, N., and Dagalp, K. (2000). Serum leptin levels in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 95, 3584-3589.
89. Vera, M., and Nieto, N. (2006). Hepatic stellate cells and alcoholic liver disease. Rev. Esp. Enferm. Dig. 98, 674-684.
90. Wagner, M., Zollner, G., and Trauner, M. (2011). Nuclear receptors in liver disease. Hepatology 53, 1023-1034.
91. Watanabe, A., Hashmi, A., Gomes, D. A., Town, T., Badou, A., Flavell, R. A., and Mehal, W. Z. (2007). Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 46, 1509-1518.
92. Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contr-eras, M., Landt, C. L., and Harrison, S. A. (2011). Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140, 124-131.
93. Yilmaz, Y., Kurt, R., Gurdal, A., Alahdab, Y. O., Yonal, O., Senates, E., Polat, N., Eren, F., Imeryuz, N., and Oflaz, H. (2011a). Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis 217, 125-129.
94. Yilmaz, Y., Yonal, O., Kurt, R., Alahdab, Y. O., Eren, F., Ozdogan, O., Celikel, C. A., Imeryuz, N., Kalayci, C., and Avsar, E. (2011b). Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand. J. Gastroenterol. 46, 91-97
95. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Fried-man,J. M. (1994). Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432